Author

V. Glaser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Assay:CITE-seq· 1 Assay:CRISPR screen· 1 Assay:proteomics· 1

Frequent Co-Authors

D. L. Wagner· 4 shared H.-D. Volk· 4 shared J. Kath· 4 shared M. Schmueck-Henneresse· 4 shared P. Reinke· 4 shared W. Du· 4 shared C. Franke· 3 shared M. Stein· 3 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

D. L. Wagner

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Gene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer

W. Du, F. Noyan, O. McCallion, V. Drosdek, J. Kath, V. Glaser, C. Fuster-Garcia, M. Yang, M. Stein, O. Weber, J. K. Polansky, T. Cathomen, E. Jaeckel, J. Hester, F. Issa, , D. L. Wagner

This paper develops a non-viral CRISPR-Cas12a method to redirect Tregs with CARs by integrating an antigen-binding domain into the CD3 epsilon gene, showing improved antigen-specific function and graft protection in a mouse model.

bioRxiv · Mar 18, 2024 · PreprintImmunology

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

J. Kath, C. Franke, V. Drosdek, W. Du, V. Glaser, C. Fuster-Garcia, M. Stein, T. Zittel, S. Schulenberg, C. E. Porter, L. Andersch, A. Kuenkele, J. Alcaniz, J. Hoffmann, H. Abken, , D. L. Wagner

This paper develops a method to integrate ζ-deficient CARs into the CD3ζ gene to create functional CAR-T and CAR-NK cells with improved safety and efficacy for off-the-shelf therapies.

bioRxiv · Nov 10, 2023 · PreprintImmunology

Matching or genetic engineering of HLA Class I and II facilitates successful allogeneic 'off-the-shelf' regulatory T cell therapy

O. McCallion, W. Du, V. Glaser, K. Milward, C. Franke, J. Kath, M. Valkov, M. Yang, A. Künkele, J. K. Polansky, M. Schmueck-Henneresse, H.-D. Volk, P. Reinke, D. L. Wagner, J. Hester, F. Issa

This study shows that matching or engineering HLA-I and HLA-II improves the efficacy of allogeneic regulatory T cells for immunoregulation.

bioRxiv · Aug 6, 2023 · PreprintImmunology

Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells

V. Glaser, C. L. Flugel, J. Kath, W. Du, V. Drosdek, C. Franke, M. Stein, A. Pruss, M. Schmueck-Henneresse, H.-D. Volk, P. Reinke, D. L. Wagner

This paper combines CRISPR nucleases to simultaneously knock-in and base edit CAR T cells, reducing translocations to 1.5% and improving safety.

bioRxiv · Nov 11, 2022Bioengineering